
Join to view full profile
818 Forest LNWaterford, WI 53185
Phone+1 262-514-3700
Fax+1 262-514-3867
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alok Srivastava, MD is a board certified internist in Waterford, Wisconsin. He is currently licensed to practice medicine in Wisconsin, Illinois, and Ohio.
Education & Training
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1995 - 1998
University of Cincinnati College of MedicineClass of 1995
Certifications & Licensure
WI State Medical License 1996 - 2027
OH State Medical License 2001 - 2010
IL State Medical License 2006 - 2008
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- 2 citationsLower-dose emicizumab prophylaxis: can less be more?Alok Srivastava, Alfonso Iorio
Journal of Thrombosis and Haemostasis. 2024-04-01 - Early detection, reactivation of cytomegalovirus DNA & immediate early (IE)-mRNA expression in hematopoietic stem cell-transplant patients.Sangeeta Thomas, Santhosh Kumar Duraisamy, Rayaz Ahmed, Aby Abraham, Auro Vishwabandhya
Indian Journal of Medical Microbiology. 2023-12-19 - 56 citationsFitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.Alok Srivastava, Savita Rangarajan, Kaan Kavakli, Robert Klamroth, Gili Kenet
The Lancet. Haematology. 2023-05-01
Press Mentions
Fitusiran Beneficial in Hemophilia a, B with or Without InhibitorsMarch 31st, 2023
Monthly Injections Might Lower Bleeding in People with HemophiliaMarch 31st, 2023
Bhubaneswar Hosts Conference on Endoscopic SurgerySeptember 25th, 2022









